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Abstract
Background: Tenascin-C (TN-C) is an extracellular matrix glycoprotein that is involved in tissue injury and repair
processes. We analyzed TN-C expression in normal and osteoarthritic (OA) human cartilage, and evaluated its
capacity to induce inflammatory and catabolic mediators in chondrocytes in vitro. The effect of TN-C on
proteoglycan loss from articular cartilage in culture was also assessed.
Methods: TN-C in culture media, cartilage extracts, and synovial fluid of human and animal joints was quantified
using a sandwich ELISA and/or analyzed by Western immunoblotting. mRNA expression of TN-C and aggrecanases
were analyzed by Taqman assays. Human and bovine primary chondrocytes and/or explant culture systems were
utilized to study TN-C induced inflammatory or catabolic mediators and proteoglycan loss. Total proteoglycan and
aggrecanase -generated ARG-aggrecan fragments were quantified in human and rat synovial fluids by ELISA.
Results: TN-C protein and mRNA expression were significantly upregulated in OA cartilage with a concomitant
elevation of TN-C levels in the synovial fluid of OA patients. IL-1 enhanced TN-C expression in articular cartilage.
Addition of TN-C induced IL-6, PGE2, and nitrate release and upregulated ADAMTS4 mRNA in cultured primary human
and bovine chondrocytes. TN-C treatment resulted in an increased loss of proteoglycan from cartilage explants in
culture. A correlation was observed between TN-C and aggrecanase generated ARG-aggrecan fragment levels in the
synovial fluid of human OA joints and in the lavage of rat joints that underwent surgical induction of OA.
Conclusions: TN-C expression in the knee cartilage and TN-C levels measured in the synovial fluid are significantly
enhanced in OA patients. Our findings suggest that the elevated levels of TN-C could induce inflammatory
mediators and promote matrix degradation in OA joints.
Background
Tenascin-C (TN-C) is a modular, multifunctional extra-
cellular matrix (ECM) glycoprotein that is associated
with tissue injury and repair. It was discovered originally
in gliomas, muscle tissue and in the nervous system,
and called by different names: myotendinous antigen,
glial/mesenchymal ECM protein, cytotactin, J1 220/200,
neuronectin and hexabrachion [1]. It was later found in
the osteotendinous junction and superficial layers of
articular cartilage [2,3]. The structure of TN-C com-
prises an amino-terminal oligomerization domain con-
sisting of heptad repeats, multiple epidermal growth
factor (EGF)-like repeats, fibronectin type III repeats
(FN-III) and a carboxyl-terminal fibrinogen-like globular
domain. It forms a hexameric 1.5 million Da form
through the formation of disulfide links N-terminal to
the triple-coiled coil region of two trimers [4].
TN-C interacts with a variety of ECM molecules and
cell surface receptors, thus affecting tissue architecture,
tissue resilience and cell responses. It plays a major role
in cell adhesion, migration, proliferation, and cellular
signaling through induction of pro-inflammatory cyto-
kines [5]. TN-C is abundantly expressed during embryo-
genesis and organogenesis. Its expression is highly
restricted in healthy adult tissues, but reappears in the
process of wound healing, regeneration, or neoplastic
events [6,7]. TN-C is associated with the development
of articular cartilage, but decreases markedly during
maturation of chondrocytes [8,9], and almost disappears
in adult cartilage [10,11]. In diseased conditions includ-
ing osteoarthritis (OA) and rheumatoid arthritis (RA),
TN-C is highly expressed in both cartilage and syno-
vium [10-13]. A correlation between TN-C levels in
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radiographic progression of knee OA [15] has been
shown.
The proinflammatory cytokine, IL-1 plays a significant
role in joint pathology, and its actions can occur
through TLR4 (Toll-like receptor-4) activation [16].
Bobacz et al. confirmed the expression of TLR4 in
human articular chondrocytes at both the mRNA and
the protein level [17]. Lipopolysaccharides (LPS) induce
catabolic effects in cartilage matrix [18]; LPS-induced
activation of TLR4 in articular chondrocytes has been
shown to decrease matrix biosynthesis [17]. TN-C was
recently identified as an endogenous DAMP (damage-
associated molecular pattern) activating TLR4 in inflam-
matory diseases [19]. TN-C is also reported to induce
cytokine and metalloprotease (MMP) synthesis in mur-
ine synovial fibroblasts via activation of a9 integrins
[20]. Intra-articular injection of TN-C promoted joint
inflammation in-vivo in mice, and mice that do not
express TN-C showed rapid resolution of acute joint
inflammation and are protected from erosive arthritis
induced by immunization and intra-articular injection of
methylated BSA [19].
The objective of the current study was to compare
cartilage mRNA and protein levels of TN-C under nor-
mal and OA conditions, and determine the effect of IL-
1o nT N - Ce x p r e s s i o ni na r t i c u l a rc a r t i l a g e .W ea l s o
evaluated the role of TN-C in inducing inflammatory
mediators and proteoglycan degradation in articular car-
tilage. TN-C levels were correlated with proteoglycan
levels in the synovial fluid samples of OA patients; and
the pattern of TN-C release as compared to aggreca-
nase-generated ARG-aggrecan fragment release into
synovial fluid was followed in a rat model of OA.
Methods
Human cartilage extract and RNA preparation
Specimens of non-OA cartilage obtained from human
donors with consent had no history of joint disorders;
they were received within 36 hours following autopsy
(National Disease Research Interchange, Philadelphia,
PA), examined macroscopically and smooth intact sur-
faces without OA-like lesions were harvested for protein
extraction and RNA preparation. The average age of the
7 non-OA donors was 43 years with an age range of 38-
58 years. Specimens of OA cartilage with visible lesions
were obtained with consent from patients undergoing
knee replacement surgery at New England Baptist Hos-
pital, and harvested within a few hours of surgery. The
average age of the 7 OA cartilage donors was 68 years
with an age range of 50-82 years. This study was per-
formed under the approval of Pfizer’s Institutional
Human Ethics Committee. Cartilage slices harvested
under sterile conditions were cut into explants (6-8 mm
width), rinsed three times in PBS, and flash frozen. Car-
tilage (1 g each) was pulverized in a Spex Certiprep free-
zer mill Model 6750 (15 Hz; 2 × 1 min with 1 min
pause between cycles) under liquid nitrogen for protein
extraction and RNA preparation. RNA was prepared
from pulverized cartilage as described [21]. For protein
extraction, the powdered cartilage was immediately sus-
pended in 10 ml of 4 M guanidine HCl, 50 mM sodium
acetate pH 5.8 containing protease inhibitor cocktail
(Calbiochem, Gibbstown, NJ) and extracted for 48 hours
at 4°C on a rotator. The mixture was then centrifuged
at 3,000 rpm for 10 min and the supernatant dialyzed
against 20 mM Tris-HCl, pH 8.2 (with protease inhibi-
tors) overnight at 4°C. OA and non-OA cartilage
extracts (5 μg protein equivalent) were deglycosylated
with 0.15 U/ml chondroitinase ABC (Sigma, St Louis,
MO), 0.15 U/ml Keratanase I and 0.0075 U/ml Kerata-
nase II (Seikagaku America, Falmouth, MA) at 37°C for
3 hours. The samples were separated on a 3-8% Tris-
Acetate gel (Invitrogen, Carlsbad, CA), transferred to
nitrocellulose membrane and probed with anti-human
Tenascin-C (EGF-like domain) antibody 4F10TT
(Immuno-Biological Laboratories Co., Ltd. Japan) at
1:100 dilution followed by incubation in anti-mouse IgG
(H&L) conjugated to alkaline phosphatase (Promega,
M a d i s o n ,W I )a t1 : 3 0 0 0d i l u t i on. Detection of reactive
bands was performed with NBT/BCIP substrate (Pro-
mega). Purified human TN-C protein (Millipore, Biller-
ica, MA) was used as a positive control in the Western
blot analysis. The blots were also probed with secondary
antibody alone to confirm specificity of detection.
Endotoxin removal
Purified human TN-C protein (Millipore) from human
glioma cell line U251 was used in the in vitro experi-
ments. Endotoxin levels in the TN-C protein samples
were measured using the Endosafe Portable Test System
(Endosafe-PTS) in a cartridge, PTS 201 with a sensitivity
range of 10-0.1 EU/ml (Charles River Laboratories, Wil-
mington, MA). The protein was taken through an endo-
toxin removal process using detoxigel endotoxin
removal columns (ThermoFisher Scientific, Waltham,
MA) following manufacturer’s protocol. The endotoxin
levels were measured again in the TN-C preparation
using the cartridge, PTS 2005 (5-0.05 EU/ml range sen-
sitivity) and the Endosafe-PTS after endotoxin removal.
Primary chondrocyte cultures
Bovine and human primary chondrocytes were prepared
under sterile conditions by pronase and collagenase
treatments followed by filtration and centrifugation as
previously described [22]. Cells were washed, resus-
pended in DMEM-F12 (Gibco, Carlsbad, CA), 10% FBS
(Sigma, St. Louis, MO), 1% antimycotic-antibiotic
Patel et al. BMC Musculoskeletal Disorders 2011, 12:164
http://www.biomedcentral.com/1471-2474/12/164
Page 2 of 14solution (Sigma), and counted on a hemocytometer. Cell
viability was determined by trypan blue dye exclusion,
cell viability was found to be >95%. Cells were plated at
1 million/well in a 24 well tissue culture plate (1 ml/
well) and maintained at 37°C. The cells were serum
starved overnight once they were confluent (in 3-4
days), and washed with serum free media before induc-
tion. LPS from E. coli R515 (Re) (Axxora, San Diego,
CA) at 0 to 1000 ng/ml or TN-C protein at 0 to 10 μg/
ml was added and incubated for 48 hours at 37°C to
study dose-dependent induction of primary chondro-
cytes. Heat killed TN-C that was heated at 100°C for 30
min, and LPS preincubated for 1 hour with polymyxin-B
(PMB; Sigma, St. Louis, MO) served as negative controls
for TN-C and LPS treatment, respectively. TN-C at 10
μg/ml preincubated with 3 μg/ml PMB was also tested
to confirm that the induction effects observed with TN-
C were not endotoxin related. TAK242, a specific TLR4
inhibitor [23], was synthesized at Pfizer. For TAK242
treatment, the cells were pretreated with inhibitor alone
for 2 hours prior to induction with 1000 ng/ml LPS or
10 μg/ml TN-C in the presence of inhibitor. The media
was removed after 48 hours of induction and analyzed
i nI L - 6 ,n i t r a t e ,a n dP G E 2 assays. Cells treated with
1000 ng/ml LPS, 10 μg/ml TN-C or 5 ng/ml IL-1b with
or without TAK242 for 48 hours were washed in PBS,
and lysed in lysis buffer for RNA preparation using
RNAeasy kit (Qiagen, Valencia, CA) following the man-
ufacturer’s protocol.
Cartilage explant cultures
Articular cartilage explant discs were harvested under
sterile conditions from young bovine metacarpal phalan-
geal joints (Research 87, Hopkinton, MA). Briefly, full-
thickness plugs were punched using a 8 mm cork borer
and cartilage discs were generated by slicing 1 mm thick
sections from the articular surface of the plugs. Discs
were rinsed in PBS and subsequently cultured in med-
ium. The medium consisted of Dulbecco’s Modified
Eagle’s medium (JRH Biosciences, Lenexa, KS), 50 μg/ml
ascorbic acid (Wako, Osaka, Japan), 10 mM HEPES
(Mediatech, Herndon, VA), 2 mM L-glutamine (Media-
tech), antibiotic-antimycotic solution (Sigma). Discs
were cultured for 5 days with one media change in a 37°
Ca n d5 %C O 2 environment to equilibrate the tissue
prior to treatment. Following equilibration, 3 discs
(~100 mg/well) were weighed and placed in 24-well tis-
sue culture plate in 1 ml medium with or without 1 or
10 ng/ml of IL-1a (Sigma, St Louis, MO) for 48 hours
for the first study. The media was tested for TN-C
levels, and RNA prepared from cartilage discs for TN-C
taqman analysis. For the second study, explants were
treated with 5 ng/ml IL-1a,1 0μg/ml TN-C, or 1000
ng/ml LPS with or without TAK242 (0.01, 0.1, or 1
μM). For TAK242 effects, explants were pre-treated
with the inhibitor for 2 hours prior to induction in the
presence of inhibitor. The media was removed for the
analysis of proteoglycan release after 48 hours of
induction.
Synovial fluid samples
Neat human knee joint synovial fluids from patients
with end stage osteoarthritis (OA; n = 8: 4 males and 4
females; 50-83 years old) were obtained from NEBH,
and synovial fluids from knee-healthy reference subjects
(Ref; n = 8: 5 males and 3 females; 45-56 years old)
were from NDRI or Northland labs with patient con-
s e n t .T h eO Ag r o u pi n c l u d e d7s y n o v i a lf l u i d so ft h e
same donors from whom cartilage samples were used
for TN-C protein and mRNA expression. Representative
OA and reference synovial fluids (15 μle a c h )f r o mt h e
above set were treated with 10 U of hyaluronidase
(Sigma) at RT overnight and subjected to Western blot
analysis with anti-human Tenascin-C (EGF-like domain)
antibody 4F10TT as described above for cartilage
extracts. The blots were probed with secondary antibody
alone to confirm specificity of detection.
Male Lewis rats weighing approximately 300 grams
were obtained from Charles River Laboratories (Wil-
mington, MA). The rats underwent medial meniscal sur-
gery in the right knee to induce joint instability leading
to cartilage degeneration as described [24]. The animals
were euthanized at different times after surgery (4 days,
1 wk, 2 wks, and 3 wks; n = 10 animals/time point).
Synovial fluid lavages and serum were collected. Five
naïve animals per time point were also included. Serum
and synovial fluid lavage urea levels in each rat were
used to correct TN-C, proteoglycan, and ARG-aggrecan
values for dilution. This study was performed under the
approval of Pfizer’s Institutional Animal Care and Use
Committee.
Biochemical assays
TN-C was measured in cartilage extracts, conditioned
media, and synovial fluid samples using the TN-C Large
ELISA kit (Immuno-Biological Laboratories Co., Ltd.
Japan). The ELISA uses anti-TN-C 19C4MS monoclonal
antibody against the FNIII-C domain for capture, and
HRP conjugated anti-TN-C 4F10TT mouse monoclonal
antibody against the EGF domain for detection. 4F10TT
binds an epitope from the EGF domain and recognizes
both the small and large TN-C variants. 19C4MS binds
an epitope of the FNIII-C domain and recognizes large
variants. The characteristics of these antibodies have
been described elsewhere [15,25]. TN-C standard in the
kit was run at 0-24 ng/ml for a standard curve. Samples
were appropriately diluted in PBS and assayed in the
TN-C ELISA using manufacturer’sp r o t o c o l .T N - C
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PBS- or mouse IgG-coated wells were included as con-
trols. To confirm specificity of TN-C detection, aggre-
can, a major cartilage proteoglycan purified from human
cartilage as described [26] was tested at various concen-
trations in the assay as a negative control. To further
confirm specificity of detection in synovial fluid, two
human synovial fluids were immunodepleted of TN-C
using anti-TN-C 4C8MS monoclonal antibody
(Immuno-Biological Laboratories Co.) against the FNIII-
B domain [27], or anti-human TN-C BC-24 (Abcam,
Cambridge, MA) against the EGF domain, and then ana-
lyzed in the ELISA. Protein-G Dynabeads (Invitrogen)
were used following manufacturer’s protocol for immu-
noprecipitation (20 μga n t i b o d y ;2 0 0μlo fs y n o v i a l
fluid), Mouse IgG was used as a negative control in
immunodepletion experiments. In order to determine
spike-in recovery of TN-C, two human synovial fluids
diluted to 1:100, 1:200, or 1:400 were spiked in with
TN-C standard at a final concentration of 5 or 10 ng/ml
and analyzed in the ELISA.
Protein was quantified using the microplate Bradford
protein assay (Thermo Scientific, Rockford, IL). Cell toxi-
city was determined in primary cell and explant cultures
by measuring lactate in the conditioned media using a
lactate assay (Trinity biotech, St. Louis, MO). Prostaglan-
din E2 (PGE2) release was measured using a PGE2 ELISA
(R&D Systems, Minneapolis MN). Measurement of
nitrate concentrations was performed using a nitrate/
nitrite colorimetric assay kit (Cayman Chemical Com-
pany, Ann Arbor, MI). Human chondrocyte conditioned
media were screened using a human proinflammatory 7-
plex MSD tissue culture kit (Meso Scale Discovery,
Gaithersburg, Maryland). Human IL-6 and IL-8 were
measured individually using MSD human cytokine assay
tissue culture kits (Meso Scale Discovery). The proteogly-
can content in bovine explant conditioned media was
measured as sulfated glycosaminoglycan (sGAG) by a
colorimetric assay with dimethylmethylene blue (Serva,
Heidelberg, Germany) [28]. Proteoglycan levels in human
synovial fluids were determined by the sGAG assay
(Kamiya Biomedical Company, Seattle, WA) [29]. ARG-
aggrecan fragments in synovial fluids were measured in
an ELISA developed at Pfizer [26].
Gene expression assays
Taqman gene expression assays were done using one-
step RT-PCR reagents and Assay on Demand primer-
probe sets (Applied BioSystems, Foster City, CA) follow-
ing manufacturer’s protocol. For analyzing bovine sam-
ples, GAPDH (Bt03210913_g1), and ADAMTS4
(Bt03224693_m1) primer/probe sets were used. For the
human samples, GAPDH (Hs99999905_m1), ADAMTS4
(Hs00192708_m1), ADAMTS5 (Hs00199841_m1), and
TN-C (Hs01115665_m1) primer/probe sets were used.
100 ng RNA per sample was tested in duplicates and
results averaged.
Statistical analysis
One-way Analysis of Variance (ANOVA) of log trans-
formed values was performed for TN-C and ARG-aggre-
can levels in human and rat joint fluids to test for
statistical significance. Student’s t-test was performed
for the TN-C protein and mRNA expression studies and
in vitro inhibition studies to test for significance. Spear-
man rank order was used for correlation analysis.
Results
TN-C mRNA expression was significantly upregulated
by approximately 6-fold (p = 0.02) in OA relative to
non-OA cartilage (Figure 1A). An ELISA, which mea-
sures large splice variants of TN-C (TN-C Large) [30],
was then used to measure TN-C protein levels. TN-C
standard or samples plated on PBS- or mouse IgG
coated wells did not produce any optical density (OD)
values in the ELISA confirming specific binding of TN-
C to 19C4MS-coated plates. Aggrecan tested as a nega-
tive control did not produce signal further confirming
the specificity of detection. OA cartilage (n = 7) had a
mean of 5.79 ng TN-C per μg total protein, which was
significantly higher (approximately 8-fold; p = 0.0006)
than the levels in non-OA cartilage (n = 7) which gave a
mean of 0.69 ng per μg total protein (Figure 1B). In the
Western immunoblot analyses of representative cartilage
extracts, we also observed increased TN-C levels in OA
cartilage extracts (Figure 1C). Two large variants of 350
and 240 kD molecular weight, and a small variant at
210 kD were observed in OA cartilage. The non-OA
cartilage extracts had only the 240 kD large variant and
the small 210 kD variant.
Purified TN-C protein (Millipore) consisting of large
variants was tested for endotoxin levels using the Endo-
safe-PTS that utilizes existing FDA-licensed LAL (Limu-
lus amaebocyte lysate) formulations loaded into a test
cartridge. The level measured prior to endotoxin
removal was 8.0 endotoxin units (EU)/mg protein. After
passing the protein through detoxigel endotoxin removal
columns, the levels dropped to < 0.05 EU/mg protein in
the Endosafe-PTS assay. When human primary chon-
drocytes were treated with varying concentrations of
TN-C or LPS (1-10 μg/ml TN-C; 0.1-1000 ng/ml LPS)
and conditioned media samples screened using the
proinflammatory 7-plex MSD kit (for IFN-g, IL-1b, IL-6,
I L - 8 ,I L - 1 0 ,I L - 1 2 p 7 0 ,a n dT N F a), only IL-6 and IL-8
were detected and found to be significantly induced by
TN-C or LPS treatments (data not shown). Individual
IL-6 and IL-8 MSD tissue culture kits were used for
further confirmation.
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release from human primary chondrocytes dose-depen-
dently resulting in 20-170 fold induction of IL-6 at 1 to
1000 ng/ml LPS, and 15-60 fold induction of IL-8 at 10
to 1000 ng/ml LPS. No significant increase over control
was observed for IL-6 at 0.1 ng/ml LPS; and for IL-8 at
0.1 and 1 ng/ml LPS (Figure 2A). IL-6 was followed up
in further experiments with chondrocytes and explants.
A dose dependent inhibition of IL-6 release by PMB
was observed; 100% inhibition of IL-6 release was seen
at 1 μg/ml PMB (Figure 2B). 1000 ng/ml LPS that was
pre-incubated with 3 μg/ml PMB served as a negative
control for LPS treatment in further experiments.
Nitrate release was induced 2-10 fold (Figure 2C) and
PGE2 release increased 350-1750 fold in a dose depen-
dent fashion when tested at 1 to 1000 ng/ml LPS. There
was no significant change in the release of nitrate and
PGE2 at 0.1 ng/ml LPS (Figure 2D).
Addition of TN-C protein (1 or 10 μg/ml) to human
chondrocyte cultures induced IL-6, IL-8, PGE2 and
nitrate in a dose dependent manner (Figure 3). TN-C
treatment resulted in an approximately 160- and 230-
fold increase in IL-6 release; 80- and 120-fold increase
in IL-8 release (Figure 3A); 3- and 8-fold increase in
nitrate release (Figure 3B); and 130- and 600-fold
increase in PGE2 (Figure 3C) release at 1 and 10 μg/ml,
respectively. TN-C at 10 μg/ml pretreated with 3 μg/ml
PMB did not show any reduction in IL-6, IL-8, nitrate
and PGE2 release. 10 μg/ml heat killed TN-C served as
a negative control in this experiment and did not show
induction of IL-6, IL-8, PGE2, or nitrate (Figure 3). The
results from PMB treated TN-C and heat killed TN-C
confirmed that the effects observed were endotoxin
independent.
Induced IL-6, PGE2, and nitrate release with 1000 ng/
ml LPS or 10 μg/ml TN-C treatment was dose-depen-
dently inhibited by TAK242. TAK242 at 1 μMr e s u l t e d
in complete inhibition of LPS or TN-C induced release
of IL-6, PGE2 and nitrate (Figure 4). Lactate concentra-
tions in the media (≥ 85% lactate compared to control
wells) confirmed that inductions and inhibitor treat-
ments were tolerated by the cells at the concentrations
used.
ADAMTS4 mRNA expression in bovine chondrocytes
was up regulated 28- and 25-fold when treated with 10
μg/ml TN-C and 1000 ng/ml LPS, respectively.
Figure 1 TN-C expression in OA vs. non-OA human cartilage. A, mRNA expression of TN-C in human cartilage expressed as Taqman units
normalized to GAPDH. Non-OA has been set to 1. n = 7 donors each group; error bars indicate SD; p = 0.02. B, Protein expression of TN-C in
cartilage as measured in the TN-C Large ELISA. N = 7 donors each group; error bars indicate SD; p = 0.0006. C, Representative OA and non-OA
cartilage extracts (5 μg protein) separated on a 3-8% tris-acetate gel, transferred, and probed with anti-TN-C (EGF-like domain) antibody, 4F10TT
that detects all forms of TN-C. Lanes are O = OA; N = Non-OA; S = standard human TN-C protein (Millipore). Bands are marked as L = large
variant and S = small variant.
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dependently suppressed by TAK242 (Figure 5A). Simi-
larly, ADAMTS4 mRNA expression was upregulated 8-
and 20-fold in human primary chondrocytes when trea-
ted with 10 μg/ml TN-C and 1000 ng/ml LPS, respec-
tively. IL-1b at 5 ng/ml that was used as a positive
control resulted in 29-fold up regulation of ADAMTS4
in human chondrocytes. (Figure 5B). In contrast to
ADAMTS4, ADAMTS5 did not show any significant
changes with TN-C, LPS or IL-1b treatment. Heat killed
TN-C at 10 μg/ml and PMB treated LPS at 1 μg/ml
served as negative controls and did not cause significant
upregulation of ADAMTS4.
IL-1a added at 0, 1, and 10 ng/ml to bovine explant
cultures increased TN-C protein in the cartilage and
also stimulated the release of TN-C into the condi-
tioned media in a dose-dependent manner (Figure 6A).
The increase in TN-C protein levels correlated with
mRNA expression in the cartilage (Figure 6B).
Proteoglycan loss was induced as measured by sGAG
release into the conditioned media of bovine explants
following 10 μg/ml TN-C or 1000 ng/ml LPS treatment,
which was similar to the loss due to 5 ng/ml IL-1a
induction (Figure 6C). IL-1a resulted in approximately
20% loss of sGAG from bovine cartilage in 48 hours.
TN-C showed a similar percentage release, whereas, the
release with LPS was slightly higher at approximately
30% loss. TAK242 (at 0.1 and 1 μM) dose dependently
reversed the loss of proteoglycan due to TN-C and LPS
t r e a t m e n t s ,b u td i dn o ta f f e c tI L - 1 a induced proteogly-
can release (Figure 6C).
Human synovial fluids depleted of TN-C with anti-
TN-C antibodies prior to testing showed 100% loss of
signal in the ELISA confirming the specificity of detec-
tion in synovial fluids. The mean spike-in recovery of
TN-C at three different dilutions tested was 89% with
a range of 78-97%. TN-C level measured in human
OA synovial fluids (n = 8) gave a mean of 380 ng/ml
Figure 2 LPS induction of primary human chondrocytes. Release of A, IL-6 and IL-8; C, nitrate; and D, PGE2 from cultured human chondrocytes
treated with 0-1000 ng/ml LPS for 48 hours. B, Dose dependent inhibition of LPS (1000 ng/ml) induced IL-6 release by polymyxin-B (PMB). PMB
was added at 3 μg/ml in C and D. The error bars indicate SD of averaged treatment results (duplicate wells) from 3 donors.
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the reference synovial fluids was 90 ng/ml (range: 44-
218 ng/ml) giving a significant 4.2-fold higher release
in the OA group as compared to the healthy reference
controls (p = 0.001). Figure 7A shows the results of
Western immunoblot analysis of representative OA
and non-OA synovial fluid samples using anti-TN-C
antibody. As in the OA cartilage extract, 350 kD and
240 kD large TN-C variants and the 210 kD small var-
iant were present in the OA synovial fluids. TN-C was
present at insignificant levels in non-OA reference
fluids. Our Western immunoblot analysis results corre-
lated with the TN-C bands reported earlier in OA
synovial fluids [14]. Upregulation of TN-C mRNA and
protein in the cartilage correlated significantly with a
simultaneous increase in the synovial fluid; the correla-
tion analysis of these factors tested in the same OA
patients have been summarized in Table 1.
A trend towards correlation was observed when TN-C
levels were correlated to aggrecanase generated ARG-
aggrecan or total proteoglycan in human synovial fluid
samples tested (Figure 7B &7C). In the rat meniscal tear
model, there was a significant 107-fold increase in TN-C
release at 4 days in surgery knees compared to no surgery
contralateral left controls or the knees of naïve animals,
the fold increase dropped to 77-, 20- and 12-fold increase
at 1-, 2- and 3-wks after joint instability induction,
respectively. The trend of TN-C release into the synovial
fluids followed the release of ARG-aggrecan in these ani-
mals; ARG-aggrecan of rat joint fluids showed a signifi-
cant 4 fold increase in the unstable right knees at 4 days
and 1 wk after surgery as compared to un-operated con-
tra-lateral left knees or naïve animals (left and right
knees), the fold increase dropped gradually at 2 and 3
wks post surgery but was significantly higher than the
controls (Figure 8A). There was a very significant correla-
tion (rs = 0.92 and p = < 0.0001) when the TN-C levels in
these samples (n = 40; fluids from left contra lateral and
right surgery knees of 5 animals per time point) were
correlated to ARG-aggrecan levels (Figure 8B).
Figure 3 TN-C treatment of primary human chondrocytes. Release of A, IL-6 and IL-8; B, nitrate; C, PGE2 from cultured human chondrocytes
treated with 0-10 μg/ml TN-C for 48 hours. HK- heat killed. 10 μg/ml heat killed TN-C served as a negative control. The error bars indicate SD of
averaged treatment results (duplicate wells) from 3 donors.
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In the current study, we found a concomitant upregula-
tion of TN-C mRNA and protein in the cartilage along
with increased TN-C in the synovial fluid of OA
patients. We have demonstrated a novel role for
increased TN-C levels in the OA joint in promoting
proteoglycan loss in addition to mediating inflammatory
signals, which is supported by a correlation between
TN-C levels in the knee synovial fluid and proteoglycan
loss from the articular cartilage in human and rat joints.
In musculoskeletal tissues, the factors regulating the
expression of TN-C are IL-1b [31], tumor necrosis fac-
tor-a (TNFa) [31], transforming growth factor-b
(TGFb)[ 3 2 ] ,a n db a s i cf i b r o b l a s tg r o w t hf a c t o r( b F G F )
[33], all of which are present at increased levels in the
joints of patients with OA compared with those of nor-
mal patients [34]. A range of TN-C variants with mass
from 350 to 210 kD are generated by alternative splicing
of FN (III) A-D repeats of TN-C RNA [35]. Studies
have shown that TN-C is localized in articular cartilage
from OA patients at the extracellular matrix underneath
the surface and pericellular compartment of the chon-
drocytes [10,11]. Chondrocytes also produce both large
and small variants during embryogenesis and develop-
ment and provide a cellular source of TN-C in the syno-
vial fluid [2,9]. We observed that both large (350 and
240 kD) and small (210 kD) variants were abundant in
OA cartilage extracts and synovial fluids when com-
pared to non-OA samples. Our findings agree with an
earlier report where all TN-C variants were found to
increase in the synovial fluid with advancing stages of
cartilage degradation [14]. Western blotting revealed
degraded fragments of TN-C of molecular weight lower
than 200 kD in OA cartilage and synovial fluid (Figure
1C &7A) that could be MMP generated [36]. The large
variants are known to be more susceptible to MMP
cleavage, such as MMP-2 and MMP-7, than the small
variant [36]. This is evidenced by the relatively lower
Figure 4 Effect of TAK242 on LPS or TN-C induced changes in primary human chondrocytes. Human chondrocytes were induced with 1000
ng/ml LPS or 10 μg/ml TN-C for 48 hours. TAK242 was present 2 hours prior to induction and during the induction period. TAK242 effects on
TN-C or LPS induced A, IL-6; B, nitrate; and C, PGE2 release. The error bars indicate SD of averaged treatments (duplicate wells) from 3 donors. *
indicates p < 0.05.
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Page 8 of 14intensity of the 350 kD large variant in OA cartilage and
synovial fluids. ILa increased TN-C levels in cartilage in
culture as well as its release into the conditioned media
indicating enhanced synthesis of TN-C by chondrocytes
in response to inflammatory stimuli, this is in agreement
with an earlier finding on ILb induced TN-C in human
cartilage [37].
LPS and other microbial components initiate signal
transduction through TLR4, resulting in the release of
inflammatory cytokines. TLR4 also binds to matrix com-
ponents that include heparin sulfate, fibronectin, bigly-
can, and hyaluronan [38]. TN-C was recently added to
t h el i s to fe n d o g e n o u sa c t i v a t o r so fT L R 4[ 1 9 ] .S i g n a l
transduction through TLR4 leads to the activation of
transcription factors, and in turn controls the expression
of proinflammatory cytokines, chemokines, and MMPs
[39,40]. Expression of TLR4 in human OA chondrocytes
and cartilage in our study was confirmed by qPCR (data
not shown). Expression of TLR4 and its adaptors have
been reported also in human OA synovium [41]. Syno-
vial tissue from OA stifle dog joints that underwent cra-
nial cruciate ligament transaction was shown to have
significantly higher TLR4 gene and protein expression
as compared to the non-OA contralateral joints [42].
TN-C levels measured in the eight human synovial
fluids (based on data availability for both TN-C and
ARG-aggrecan levels) included in the study ranged from
0.11-0.82 μg/ml. However, we have measured levels up
to 5 μg/ml in several other human OA synovial fluids
tested. TN-C in dog synovial fluid after anterior cruciate
ligament transection (ACLT) also went up to 5 μg/ml
similar to human OA samples (data not shown). A dose
of 1-10 μg/ml TN-C was used in our in vitro experi-
ments to keep the treatment level close to physiological
levels in the joint under diseased conditions. TN-C
induced inflammatory mediators including IL-6, IL-8,
nitrate and PGE2 in the cartilage in vitro in a fashion
similar to LPS in our study. TAK242, the TLR4 specific
small molecule inhibitor binds strongly and specifically
to TLR4. It inhibits TLR4 signaling by binding to
Cys747 in the intracellular domain of TLR4 [43]. We
used TAK242 to confirm that the role of TN-C in indu-
cing inflammatory mediators in articular cartilage is
TLR4-dependent. Our results agree with the earlier find-
ings in human macrophages and fibroblasts from syno-
via of RA patients [19].
Loss of ECM from articular cartilage is a central event
that leads to joint destruction in arthritic diseases.
Aggrecan is a major component of the ECM responsible
for weight bearing, and an important factor in the reten-
tion of collagen within matrix [44]. Aggrecanases are
responsible for degrading aggrecan in articular cartilage
[45]. TN-C upregulated ADAMTS4 expression in chon-
drocytes in vitro via TLR4 signaling that reflected in
increased loss of sGAG from the cartilage matrix. We
tested the effect of added LPS (1000 ng/ml) or TN-C
(10 μg/ml) for 48 hrs on aggrecan mRNA expression in
human primary chondrocytes using Taqman assays and
found no significant regulation in aggrecan expression
with treatment. TN-C or LPS treatment at the above
concentrations and duration also did not result in any
significant change in the proliferation rate of the pri-
mary cells tested by the bromodeoxyuridine incorpora-
tion method (data not shown). Proteoglycan loss
measured as sGAG might indicate regeneration of carti-
lage, however, lack of TN-C or LPS induced changes in
the proliferation rate and in aggrecan expression sug-
gests that the enhanced release of sGAG results from
matrix degradation; this is supported by the observed
upregulation of ADAMTS4 in response to TN-C or LPS
treatment. ADAMTS5 did not respond to induction
Figure 5 TN-C or LPS treatment and ADAMTS expression in
primary chondrocytes. A, Bovine chondrocytes were induced with
10 μg/ml TN-C or 1000 ng/ml LPS for 48 hours with or without
TAK242. TAK242 was present 2 hours prior to induction and during
the induction period. B, Human chondrocytes were induced with 10
μg/ml TN-C, 1000 ng/ml LPS, or 5 ng/ml IL-1b for 48 hours. Cells
were lysed, RNA prepared and taqman assays performed with 50 ng
RNA/well. HK = heat killed. ADAMTS = A Disintegrin And
Metalloproteinase with Thrombospondin Motifs. The error bars
indicate SD of treatments done in triplicates, each RNA sample from
treatments/wells was tested in duplicates in the Taqman assay and
results averaged. * p < 0.05.
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Page 9 of 14with LPS, TN-C or IL-1b in our primary chondrocyte
induction experiments, consistent with earlier reports
on induced gene expression in cartilage [46,47]. How-
ever, TN-C has been shown to be upstream in the regu-
lation of several MMPs in synovial fibroblasts [48].
Increased levels of TN-C in the joint fluid significantly
correlated with cartilage TN-C mRNA and protein levels
in OA patients (Table 1). Similarly, correlating with
enhanced release of TN-C from rat joints due to surgi-
cal induction of OA, we observed a slight but statisti-
cally significant upregula t i o no fT N - Cm R N Ai nt h e
transcriptional profiling studies of cartilage from the
knees of rats that underwent meniscal tear as compared
to cartilage from the contralateral knees (34% upregula-
tion; p = 0.009), 2 weeks post surgery. Our findings on
correlation between TN-C levels and proteoglycan loss
in human and rat joints are consistent with a recent
report showing decreased proteoglycan staining accom-
panied by increased tenascin deposition in human carti-
lage with OA lesions [49]. The correlation between TN-
C and aggrecan loss could result from two different
roles of TN-C: 1) TLR4 dependent TN-C induction of
matrix degradation whereby TN-C regulates the expres-
sion metalloproteases and 2) Loss of TN-C along with
degraded fragments of aggrecan resulting from aggreca-
nase activity in diseased cartilage as TN-C binds to the
alternatively spliced G3 domain of aggrecan [50]. Our
results suggest an important role for TLR4 in the patho-
logical process initiated by elevated TN-C in the dis-
eased joints; testing TAK242 in the rat meniscal tear
model of OA might provide additional information.
Increased intensity of TN-C staining has been
observed in areas of damaged human OA cartilage com-
pared with normal cartilage [51], and a strong correla-
tion between joint fluid TN-C levels and OA severity
has also been reported [14]. A role for TN-C in the
assembly of the chondrocyte matrix has been reported
[52]. Treatment of human articular chondrocytes with
TN-C was also shown to accelerate chondrocyte prolif-
eration and play a role in cartilage repair [49]. These
findings suggest involvement of TN-C in tissue remodel-
ing that occurs in conjunction with degeneration and
repair, which is further emphasized by the delay in
articular cartilage repair observed for TN-C-deficient
Figure 6 IL-1a induced TN-C synthesis and LPS/TN-C dependent proteoglycan loss in bovine explant cultures. Bovine explants (3 discs/well)
were induced with IL-1a (0, 1, 10 ng/ml) for 48 hours and A, cartilage extracts and conditioned media analyzed in the TN-C Large ELISA. The
error bars indicate SD of treatments done in triplicates; B, cartilage RNA prepared and TN-C taqman analysis performed with 50 ng RNA/well.
The error bars indicate SD of treatments done in triplicates; each RNA sample from treatments/wells was tested in duplicates in the Taqman
assay and results averaged. * p < 0.05. C, Bovine explants (3 discs/well) were induced with 1000 ng/ml LPS, 10 μg/ml TN-C or 5 ng/ml IL-1a in
the presence or absence of TAK242 (0, 0.01, 0.1, or 1 μM) for 48 hours and the conditioned media analyzed for sGAG content. * p < 0.05.
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Page 10 of 14mice [53]. Indeed, we observed a pronounced increase
in TN-C release into the joint fluid immediately after
surgery in the rat model of OA/joint injury (Figure 8);
TN-C levels decreased with time after surgery, indicat-
ing the transient expression of TN-C during the repair
process. Similar patterns of TN-C release with a pro-
nounced increase immediately after injury/disease onset
that gradually reduced over time was observed when
human knee synovial fluids from acute cruciate ligament
injury, meniscal injury, and acute inflammatory arthritis
patients were tested (data not shown).
We hypothesize that TN-C which reappears to
attempt repair and remodeling in the OA joint could
induce cytokines, inflammatory mediators, and matrix
degrading enzymes and result in propagation of inflam-
mation and matrix degradation through TLR4 signaling.
TLR4 expression has been shown to increase in human
OA cartilage lesions, and TLR4 ligands strongly induce
catabolic responses in human chondrocytes including
production of MMPs 1, 3, and 13 and of nitric oxide
(NO), and PGE2, as well as a significant increase in the
release of proteoglycan and type II collagen degraded
products; treatment with TLR4 ligands led to phosphor-
ylation of p38, ERK, and JNK, and activation of NFB
[54]. The active domain of TN-C that activates cells in
the joint has been mapped to the fibrinogen-like globe
of the molecule [19]. Stimulation of cytokines in
Figure 7 TN-C in human synovial fluids and its correlation to proteoglycan release.A ,W e s t e r nb l o ta n a l y s i sof human synovial fluid.
Representative samples (15 μl each) were treated with 10 U of hyaluronidase overnight at RT, separated on a 3-8% tris-acetate gel, transferred,
and probed with anti-TN-C (EGF-like domain) antibody, 4F10TT that detects all forms of TN-C. Lanes are N = synovial fluid of non-OA reference
subjects; O = synovial fluid of OA patients. Bands are marked as L for large variants and S for small variants. B, Correlation analysis of TN-C vs.
ARG-aggrecan in human synovial fluid. C, Correlation analysis of TN-C vs. total proteoglycan in human synovial fluid. For both B and C, N = 8
each group; triangles represent non-OA reference subjects and circles represent OA patients.
Table 1 Correlation analysis of TN-C protein and mRNA














Note: TN-C in the synovial was measured in the ELISA that quantifies only
large variants of TN-C. SF: synovial fluid; N = 7 each from the same
individuals; Spearman rank order was used for correlation analysis; P indicates
p values.
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dependent [19]; MyD88 knockdown in human chondro-
cytes inhibited IL-1 induced expression of metallopro-
teases [55] suggesting MyD88 as a potential target in
addition to TLR4 to intervene cartilage degradation. The
rat meniscal tear model of OA and the TN-C time
course release pattern explored in this study could serve
to evaluate TLR4 or MyD88 inhibitors, and in turn con-
firm the role of TLR4 signaling and TN-C in OA pro-
gression. Further studies to explore the signaling
pathway of TN-C induced TLR4 in chondrocytes that
leads to inflammation and cartilage matrix degradation
are warranted.
Conclusions
TN-C mRNA and protein are upregulated in articular
cartilage along with an increase in TN-C levels in the
synovial fluid of OA patients. TN-C is inducible in pri-
mary chondrocytes by the inflammatory cytokine, IL-1;
it is capable of stimulating further inflammatory media-
tors and promoting proteoglycan degradation in articu-
lar cartilage in vitro. TN-C release into the joint fluid
correlates with aggrecan loss in human and rat OA
joints. De-novo expression of TN-C appears to be a reli-
able marker of joint injury/disease.
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